| Symbol | IRON |
|---|---|
| Name | DISC MEDICINE, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | United States |
| Telephone | (617) 674-9274 |
| Fax | — |
| — | |
| Website | https://www.discmedicine.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001816736 |
| Description | Disc Medicine Inc is a clinical-stage biopharmaceutical company that is dedicated to transforming the lives of patients with hematologic disorders. The company is building a portfolio of innovative therapeutic candidates that affect fundamental pathways of red blood cell biology. Disc Medicine is committed to developing treatments that empower and bring hope to the many patients who suffer from hematologic disease. The firms pipeline includes investigational product candidates that affect heme biosynthesis and iron metabolism. Additional info from NASDAQ: |
Disc Medicine Announces Multiple Presentations Across Portfolio at the European Hematology Association (EHA) 2026 Congress
Read moreINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Disc Medicine, Inc. - IRON
Read more(30% Negative) DISC MEDICINE, INC. (IRON) Reports Q2 2026 Financial Results
Read moreDisc Medicine Reports First Quarter 2026 Financial Results and Provides Business Update
Read moreINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Disc Medicine, Inc. - IRON
Read moreNew Form ARS - Disc Medicine, Inc. <b>Filed:</b> 2026-04-28 <b>AccNo:</b> 0001193125-26-187768 <b>Size:</b> 3 MB
Read moreNew Form DEFA14A - Disc Medicine, Inc. <b>Filed:</b> 2026-04-28 <b>AccNo:</b> 0001193125-26-187671 <b>Size:</b> 462 KB
Read moreNew Form DEF 14A - Disc Medicine, Inc. <b>Filed:</b> 2026-04-28 <b>AccNo:</b> 0001193125-26-187646 <b>Size:</b> 9 MB
Read moreDisc Medicine Announces Oral Presentation of Data from RALLY-MF Phase 2 Trial of DISC-0974 in Patients with Myelofibrosis and Anemia at the American Society of Clinical Oncology (ASCO) Annual Meeting
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT07368972 | Study of DISC-0974-201 in Participants With IBD and Anemia | Phase2 | Inflammatory Bowel Disease (IBD) | Recruiting | 2026-02-20 | 2027-03-01 | ClinicalTrials.gov |
| NCT07187973 | A Phase 1b, Open-Label Study of DISC-3405 in Participants With Sickle Cell Dise… | Phase1 | Sickle Cell Disease | Recruiting | 2026-01-06 | 2027-10-01 | ClinicalTrials.gov |
| NCT06985147 | A Phase 2, Open-Label Study of DISC-3405 in Participants With Polycythemia Vera… | Phase2 | Polycythemia Vera (PV) | Recruiting | 2025-08-12 | 2029-02-01 | ClinicalTrials.gov |
| NCT06910358 | Study of Bitopertin in Participants With EPP or XLP (APOLLO) | Phase3 | Erythropoietic Protoporphyria (EPP) | Active_Not_Recruiting | 2025-04-04 | 2026-10-01 | ClinicalTrials.gov |
| NCT06050915 | A Study of DISC-3405 in Healthy Volunteers | Phase1 | Healthy Volunteer | Completed | 2023-10-03 | 2024-07-09 | ClinicalTrials.gov |
| NCT05883748 | HELIOS: Open-Label, Long-Term Extension Study to Investigate the Safety, Tolera… | Phase2 | Erythropoietic Protoporphyria | Enrolling_By_Invitation | 2023-08-31 | 2028-06-01 | ClinicalTrials.gov |
| NCT05745883 | Study of DISC-0974 to Assess the Safety, Tolerability, PK and PD of DISC-0974 i… | Phase1 | Chronic Kidney Diseases | Completed | 2023-04-04 | 2026-01-16 | ClinicalTrials.gov |
| NCT05308472 | Study of Bitopertin to Evaluate the Safety, Tolerability, Efficacy, and PPIX Co… | Phase2 | Erythropoietic Protoporphyria | Completed | 2022-10-31 | 2024-08-23 | ClinicalTrials.gov |
| NCT05320198 | Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodyspla… | Phase1 | Myelofibrosis; Anemia | Recruiting | 2022-06-06 | 2026-09-01 | ClinicalTrials.gov |
| NCT04999527 | Study to Evaluate the Safety, Tolerability, PK and PD of DISC-0974 in Healthy S… | Phase1 | Healthy Volunteer | Completed | 2021-08-10 | 2022-06-30 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| DISC-0974 | Other | Phase PHASE1 | Myelofibrosis; Anemia | RECRUITING | NCT05320198 |
| DISC-0974 | Other | Phase PHASE1 | Myelofibrosis; Anemia | RECRUITING | NCT05320198 |
| DISC-0974 | Other | Phase PHASE1 | Myelofibrosis; Anemia | RECRUITING | NCT05320198 |
| DISC-0974 | Other | Phase PHASE1 | Myelofibrosis; Anemia | RECRUITING | NCT05320198 |
| DISC-0974 | Other | Phase PHASE1 | Myelofibrosis; Anemia | RECRUITING | NCT05320198 |
| DISC-3405 | Other | Phase PHASE1 | Sickle Cell Disease | RECRUITING | NCT07187973 |
| DISC-0974 | Other | Phase PHASE1 | Myelofibrosis; Anemia | RECRUITING | NCT05320198 |
| DISC-3405 | Other | Phase PHASE1 | Sickle Cell Disease | RECRUITING | NCT07187973 |
| DISC-3405 | Other | Phase PHASE1 | Sickle Cell Disease | RECRUITING | NCT07187973 |
| DISC-3405 | Other | Phase PHASE1 | Sickle Cell Disease | RECRUITING | NCT07187973 |
| DISC-3405 | Other | Phase PHASE1 | Sickle Cell Disease | RECRUITING | NCT07187973 |
| DISC-3405 | Other | Phase PHASE1 | Sickle Cell Disease | RECRUITING | NCT07187973 |
| DISC-1459 | Other | Phase PHASE3 | Erythropoietic Protoporphyria (EPP) | ACTIVE_NOT_RECRUITING | NCT06910358 |
| Placebo | Other | Phase PHASE3 | Erythropoietic Protoporphyria (EPP) | ACTIVE_NOT_RECRUITING | NCT06910358 |
| DISC-1459 | Other | Phase PHASE3 | Erythropoietic Protoporphyria (EPP) | ACTIVE_NOT_RECRUITING | NCT06910358 |
| Placebo | Other | Phase PHASE3 | Erythropoietic Protoporphyria (EPP) | ACTIVE_NOT_RECRUITING | NCT06910358 |
| DISC-1459 | Other | Phase PHASE3 | Erythropoietic Protoporphyria (EPP) | ACTIVE_NOT_RECRUITING | NCT06910358 |
| Placebo | Other | Phase PHASE3 | Erythropoietic Protoporphyria (EPP) | ACTIVE_NOT_RECRUITING | NCT06910358 |
| DISC-1459 | Other | Phase PHASE3 | Erythropoietic Protoporphyria (EPP) | ACTIVE_NOT_RECRUITING | NCT06910358 |
| Placebo | Other | Phase PHASE3 | Erythropoietic Protoporphyria (EPP) | ACTIVE_NOT_RECRUITING | NCT06910358 |
| DISC-1459 | Other | Phase PHASE3 | Erythropoietic Protoporphyria (EPP) | ACTIVE_NOT_RECRUITING | NCT06910358 |
| Placebo | Other | Phase PHASE3 | Erythropoietic Protoporphyria (EPP) | ACTIVE_NOT_RECRUITING | NCT06910358 |
| DISC-1459 | Other | Phase PHASE3 | Erythropoietic Protoporphyria (EPP) | ACTIVE_NOT_RECRUITING | NCT06910358 |
| Placebo | Other | Phase PHASE3 | Erythropoietic Protoporphyria (EPP) | ACTIVE_NOT_RECRUITING | NCT06910358 |
| DISC-3405 | Other | Phase PHASE1 | Sickle Cell Disease | RECRUITING | NCT07187973 |
| DISC-3405 | Other | Phase PHASE1 | Sickle Cell Disease | RECRUITING | NCT07187973 |
| DISC-3405 | Other | Phase PHASE1 | Sickle Cell Disease | RECRUITING | NCT07187973 |
| DISC-3405 | Other | Phase PHASE1 | Sickle Cell Disease | RECRUITING | NCT07187973 |
| DISC-3405 | Other | Phase PHASE1 | Sickle Cell Disease | RECRUITING | NCT07187973 |
| DISC-3405 | Other | Phase PHASE1 | Sickle Cell Disease | RECRUITING | NCT07187973 |
| DISC-3405 | Other | Phase PHASE1 | Sickle Cell Disease | RECRUITING | NCT07187973 |
| DISC-3405 | Other | Phase PHASE1 | Sickle Cell Disease | RECRUITING | NCT07187973 |
| Placebo | Other | Phase PHASE2 | Inflammatory Bowel Disease (IBD) | RECRUITING | NCT07368972 |
| DISC-0974 | Other | Phase PHASE2 | Inflammatory Bowel Disease (IBD) | RECRUITING | NCT07368972 |
| Placebo | Other | Phase PHASE2 | Inflammatory Bowel Disease (IBD) | RECRUITING | NCT07368972 |
| DISC-0974 | Other | Phase PHASE2 | Inflammatory Bowel Disease (IBD) | RECRUITING | NCT07368972 |
| Placebo | Other | Phase PHASE2 | Inflammatory Bowel Disease (IBD) | RECRUITING | NCT07368972 |
| DISC-0974 | Other | Phase PHASE2 | Inflammatory Bowel Disease (IBD) | RECRUITING | NCT07368972 |
| Placebo | Other | Phase PHASE2 | Inflammatory Bowel Disease (IBD) | RECRUITING | NCT07368972 |
| DISC-0974 | Other | Phase PHASE2 | Inflammatory Bowel Disease (IBD) | RECRUITING | NCT07368972 |
| Placebo | Other | Phase PHASE2 | Inflammatory Bowel Disease (IBD) | RECRUITING | NCT07368972 |
| DISC-0974 | Other | Phase PHASE2 | Inflammatory Bowel Disease (IBD) | RECRUITING | NCT07368972 |
| Placebo | Other | Phase PHASE2 | Inflammatory Bowel Disease (IBD) | RECRUITING | NCT07368972 |
| DISC-0974 | Other | Phase PHASE2 | Inflammatory Bowel Disease (IBD) | RECRUITING | NCT07368972 |
| Placebo | Other | Phase PHASE2 | Inflammatory Bowel Disease (IBD) | RECRUITING | NCT07368972 |
| DISC-0974 | Other | Phase PHASE2 | Inflammatory Bowel Disease (IBD) | RECRUITING | NCT07368972 |
| Placebo | Other | Phase PHASE2 | Inflammatory Bowel Disease (IBD) | RECRUITING | NCT07368972 |
| DISC-0974 | Other | Phase PHASE2 | Inflammatory Bowel Disease (IBD) | RECRUITING | NCT07368972 |
| Placebo | Other | Phase PHASE2 | Inflammatory Bowel Disease (IBD) | RECRUITING | NCT07368972 |
| DISC-0974 | Other | Phase PHASE2 | Inflammatory Bowel Disease (IBD) | RECRUITING | NCT07368972 |
| Placebo | Other | Phase PHASE2 | Inflammatory Bowel Disease (IBD) | RECRUITING | NCT07368972 |
| DISC-0974 | Other | Phase PHASE2 | Inflammatory Bowel Disease (IBD) | RECRUITING | NCT07368972 |
| Placebo | Other | Phase PHASE2 | Inflammatory Bowel Disease (IBD) | RECRUITING | NCT07368972 |
| DISC-0974 | Other | Phase PHASE2 | Inflammatory Bowel Disease (IBD) | RECRUITING | NCT07368972 |
| Placebo | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT04999527 |
| DISC-0974 | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT04999527 |
| Placebo | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT06050915 |
| DISC-3405 | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT06050915 |
| Placebo | Other | Phase PHASE1 | Chronic Kidney Diseases | COMPLETED | NCT05745883 |
| DISC-0974 | Other | Phase PHASE1 | Chronic Kidney Diseases | COMPLETED | NCT05745883 |
| DISC-1459 | Other | Phase PHASE2 | Erythropoietic Protoporphyria | ENROLLING_BY_INVITATION | NCT05883748 |
| Placebo | Other | Phase PHASE2 | Erythropoietic Protoporphyria | COMPLETED | NCT05308472 |
| DISC-1459 | Other | Phase PHASE2 | Erythropoietic Protoporphyria | COMPLETED | NCT05308472 |
| DISC-3405 | Other | Phase PHASE2 | Polycythemia Vera (PV) | RECRUITING | NCT06985147 |
| DISC-0974 | Other | Phase PHASE1 | Myelofibrosis; Anemia | RECRUITING | NCT05320198 |
| DISC-3405 | Other | Phase PHASE1 | Sickle Cell Disease | RECRUITING | NCT07187973 |
| DISC-1459 | Other | Phase PHASE3 | Erythropoietic Protoporphyria (EPP) | ACTIVE_NOT_RECRUITING | NCT06910358 |
| Placebo | Other | Phase PHASE3 | Erythropoietic Protoporphyria (EPP) | ACTIVE_NOT_RECRUITING | NCT06910358 |
| Placebo | Other | Phase PHASE2 | Inflammatory Bowel Disease (IBD) | RECRUITING | NCT07368972 |
| DISC-0974 | Other | Phase PHASE2 | Inflammatory Bowel Disease (IBD) | RECRUITING | NCT07368972 |
| DISC-0974 | Other | Phase PHASE1 | Myelofibrosis; Anemia | RECRUITING | NCT05320198 |
| DISC-0974 | Other | Phase PHASE1 | Myelofibrosis; Anemia | RECRUITING | NCT05320198 |
| DISC-0974 | Other | Phase PHASE1 | Myelofibrosis; Anemia | RECRUITING | NCT05320198 |
| DISC-0974 | Other | Phase PHASE1 | Myelofibrosis; Anemia | RECRUITING | NCT05320198 |
| DISC-0974 | Other | Phase PHASE1 | Myelofibrosis; Anemia | RECRUITING | NCT05320198 |
| DISC-0974 | Other | Phase PHASE1 | Myelofibrosis; Anemia | RECRUITING | NCT05320198 |
| DISC-0974 | Other | Phase PHASE1 | Myelofibrosis; Anemia | RECRUITING | NCT05320198 |
| DISC-0974 | Other | Phase PHASE1 | Myelofibrosis; Anemia | RECRUITING | NCT05320198 |
| DISC-0974 | Other | Phase PHASE1 | Myelofibrosis; Anemia | RECRUITING | NCT05320198 |
| DISC-0974 | Other | Phase PHASE1 | Myelofibrosis; Anemia | RECRUITING | NCT05320198 |
| DISC-0974 | Other | Phase PHASE1 | Myelofibrosis; Anemia | RECRUITING | NCT05320198 |
| DISC-0974 | Other | Phase PHASE1 | Myelofibrosis; Anemia | RECRUITING | NCT05320198 |
| Placebo | Other | Phase PHASE1 | Chronic Kidney Diseases | COMPLETED | NCT05745883 |
| DISC-0974 | Other | Phase PHASE1 | Chronic Kidney Diseases | COMPLETED | NCT05745883 |
| Placebo | Other | Phase PHASE1 | Chronic Kidney Diseases | COMPLETED | NCT05745883 |
| DISC-0974 | Other | Phase PHASE1 | Chronic Kidney Diseases | COMPLETED | NCT05745883 |
| Placebo | Other | Phase PHASE1 | Chronic Kidney Diseases | COMPLETED | NCT05745883 |
| DISC-0974 | Other | Phase PHASE1 | Chronic Kidney Diseases | COMPLETED | NCT05745883 |
| Placebo | Other | Phase PHASE1 | Chronic Kidney Diseases | COMPLETED | NCT05745883 |
| DISC-0974 | Other | Phase PHASE1 | Chronic Kidney Diseases | COMPLETED | NCT05745883 |
| Placebo | Other | Phase PHASE1 | Chronic Kidney Diseases | COMPLETED | NCT05745883 |
| DISC-0974 | Other | Phase PHASE1 | Chronic Kidney Diseases | COMPLETED | NCT05745883 |
| Placebo | Other | Phase PHASE1 | Chronic Kidney Diseases | COMPLETED | NCT05745883 |
| DISC-0974 | Other | Phase PHASE1 | Chronic Kidney Diseases | COMPLETED | NCT05745883 |
| Placebo | Other | Phase PHASE1 | Chronic Kidney Diseases | COMPLETED | NCT05745883 |
| DISC-0974 | Other | Phase PHASE1 | Chronic Kidney Diseases | COMPLETED | NCT05745883 |
| Placebo | Other | Phase PHASE2 | Inflammatory Bowel Disease (IBD) | RECRUITING | NCT07368972 |
| DISC-0974 | Other | Phase PHASE2 | Inflammatory Bowel Disease (IBD) | RECRUITING | NCT07368972 |
| DISC-3405 | DRUG | Phase PHASE1 | Sickle Cell Disease | RECRUITING | NCT07187973 |
| DISC-1459 | DRUG | Phase PHASE3 | Erythropoietic Protoporphyria (EPP) | RECRUITING | NCT06910358 |
| Placebo | DRUG | Phase PHASE2 | Inflammatory Bowel Disease (IBD) | RECRUITING | NCT07368972 |
| DISC-0974 | DRUG | Phase PHASE2 | Inflammatory Bowel Disease (IBD) | RECRUITING | NCT07368972 |